Transoral robotic surgery and XXXX status: Oncologic results.

@entity1 @entity957 @entity1082
BACKGROUND: @entity1 with @entity957 ( @entity957 ) have been shown to have distinct outcome profiles based on their @entity1082 ) status. The purpose of this study was to assess HPV-related outcomes after transoral robotic surgery (TORS) with adjuvant therapy as indicated. METHODS: This study consisted of a retrospective review of 50 @entity1 with @entity957 within a prospective single-arm cohort study. Outcome measures included HPV status, margin status, relapse pattern, and survival. RESULTS: Thirty-seven @entity1 were HPV-positive (74.0%) with 34 @entity1 (91.9%) being serotype-16. Negative margins were achieved in 92.3% (HPV-negative) and 94.6% (HPV-positive). In the HPV-negative group, there were no local recurrences and 1 @entity1 had both regional and distant recurrence (7.7%). In the HPV-positive group, there were no local or regional recurrences and 2 @entity1 (5.4%) had distant recurrences. There were no statistically significant differences in survival between the 2 cohorts (overall survival, disease-specific survival, disease-free survival). CONCLUSION: TORS as a primary surgical modality, followed by adjuvant therapy as indicated, offers disease control in both HPV-negative and HPV-positive groups. We believe that multi-institutional studies are warranted to further evaluate this novel approach for @entity1 who are HPV negative and HPV positive.
